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Abstract: Diabetes mellitus is a clinical syndrome characterized by 
hyperglycemia due to absolute or relative insufficiency of insulin in the body. 
Diabetic nephropathy is a generic term referring to deleterious effect on renal 
structure and/or function caused by diabetes mellitus.  In this paper, we estimate 
the probability of occurrence of diabetic nephropathy, taking serum creatinine as 
a marker for renal function/dysfunction. We adopted a Zero truncated binomial 
distribution (ZTBD) with parameters (ni, p), where p, the probability that serum 
creatinine ≥ cutoff value, was unknown. Maximum likelihood and residual 
bootstrapping methods were used to estimate p. Retrospective data was collected 
from 132 patients diagnosed as diabetic as per ADA standards. Out of the 
available data of 132 patients, 72 patients had no diabetic renal complications 
with serum  creatinine  mean ± s.d as 0.9774± 0.12508 and 60 patients had 
certain diabetic complications with serum creatinine  mean ± s.d. as 1.6462 
±0.28827.The mean ± s.d. for duration of disease for 60 patients came out to be 
15.46667± 5.54 (yrs) and median as 17.1 yrs. The two groups of patients were 
found to be significantly different with p<.001. The value of  came out to be 
0.4555397 and 0.445545 using maximum likelihood and residual bootstrapping 
methods respectively. It was found that 60 patients had non -zero probability of 
renal disease under ZTBD. From this study, it was concluded that the duration of 
diabetes along with elevated levels of serum creatinine defines a high risk group 
for the diabetic nephropathy. 
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1. Introduction 
 
Diabetes mellitus is a clinical syndrome characterized by hyperglycemia due to absolute or 
relative insufficiency of insulin in the body.  Diabetic Nephropathy (DN) is a generic term 
referring to deleterious effect on renal structure and/or function caused by diabetes mellitus. 
Type 2 diabetes usually starts in middle age or later [1]. According to World Health Organization 
estimates diabetes affects more than 170 million people worldwide and this number may rise to 
370 million by 2030 [3].The prevalence of  DN is the highest among the Asians and  is a 
growing public health concern. Diabetic nephropathy develops in 20 - 40% of patients within 10 
to 15 years after the onset of diabetes [13]. Estimating Glomerular filtration rate (GFR) is the 
most rational noninvasive method of assessing the renal status in patients [4,5].With the 
development of DN, serum creatinine (SrCr) levels start to increase and GFR starts to fall. The 
rate of rise in SrCr ,a well-accepted marker for the progression of DN, (creatinine value  1.4 to 
3.0 mg/dl) is the indicator for impaired renal function [7]. BioStratum at their 64th Scientific 
Sessions ADA Meet accepted rate of rise in serum creatinine as a marker for the progression of 
diabetic nephropathy.  Diabetic nephropathy is a leading cause of end stage renal failure [9]. 
Andersen [18] proposed multistate proportional hazards regression models with time dependent 
covariates to find mortality and incidence of nephropathy in diabetic patients. He also computed 
the transition intensities and probabilities. Frydman Halina [12] used three state time 
homogenous Markov process with irreversible transitions to find transition intensities and 
probabilities and illustrated this model with diabetic survival data. Enzo Ballone and others [17] 
applied conditional probability to find that a diabetic patient will develop a second complication, 
given that they had already developed the first complication. They also proposed the Bayes' 
formula for the same problem. Gunnes Nina and others [10] developed non-Markov multistage 
models under dependent censoring for estimating stage occupation probabilities. They showed 
that the individual transition and censoring mechanisms are linked together through covariate 
processes that affect both the transition intensities and the censoring hazard for the 
corresponding subjects. Study on development of nephropathy among diabetic patients is used as 
demonstration on how the estimation method works in practice. 
Based on the previous results, in this study also SrCr is taken as a marker for predicting renal 
health.  Present study deals with diabetic patient’s renal health. We  applied zero truncated 
binomial distribution (ZTBD)with parameters (ni,p) where ni, denoting the  number of times the 
test was recommended to the i
th
 patient, were known and p, denoting the  probability that SrCr ≥ 
cutoff value (considered as success),was  unknown . The estimated value of p, i.e p , is  derived 
using maximum likelihood and residual bootstrapping methods. Mean, variance and the 95% 
confidence band of both the estimators are also compared. The p estimators obtained from both 
the methods are used to obtain the probability of occurrence of diabetic Nephropathy under 
ZTBD. We found that 60 subjects had non -zero probability of renal disease under ZTBD. 
Further, 27 out of 60 were found to be with advanced diabetic Nephropathy.  
Although much work has already been done on diabetic nephropathy but to the best of our 
Knowledge this is the first investigation about the estimation of occurrence of nephropathy 
arising out of type-2 diabetes only. This study clearly points out the number of times the value of 
serum creatinine, if crossed normal range, could lead to renal complications. This could be an 
important pointer for medical fraternity to guide the patients about likely outcome i.e. end-stage 
renal disease.  
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Besides introduction this paper includes three more sections. Section-2, which is further divided 
into two sections, 2.1section contains details of the material used and in section 2.2 the model is 
introduced. In section-3 the model is applied to the type-2 diabetic patient data and section 4 
contains discussion. 
 
 
2. Materials and Methods 
 
2.1 Materials 
 
Retrospective data from 250 patients were short – listed who were diagnosed of diabetes [as per 
ADA standards] from the data base of Dr. Lal’s Path Lab, a reputed NABL certified path lab. 
Requests were sent to patients for sharing their pathological history in terms of up-to-date 
reports. Out of this 164 patients responded positively.  These 164 patients were contacted 
through a house to house survey and their pathological reports along with doctor’s prescription 
were collected for further verification. Reports from only 132 patients, with minimum 5 yrs 
diabetic history, were found suitable for this study as their reports indicated continuity of 
pathological follow-up always using the same lab. This was done to maintain benchmark of the 
data used.  Patients included in this study were under medical supervision.  ADA standards are 
taken as reference values for this study: FBG≥126 mg/dl for diabetes and DBP>90mmHg for 
hypertension, LDL ≥ 100 mg/dl for elevated cholesterol concentration, SrCr ≥ 1.4 mg/dl for 
onset of renal disease/nephropathy. Pathological history were recorded on SrCr, fasting blood 
glucose (FBG), diastolic blood pressure  (DBP) and low density lipoprotein (LDL). Since the 
study is concentrated on the renal complication arising out of type-2 diabetes only, it 
automatically excludes its effect on eyes, heart etc. We also excluded the cases where renal 
complication had preceded the onset of diabetes. The descriptive statistics of 132 patients is 
given in table 1. 
 
2.2 Methodology 
The Model ZTBD is depicted in figure 1. All the patients under study experienced an initial 
event E1 (diagnosed as diabetes as per ADA standards) but not all of them experienced a second 
event E2 (onset of renal disease/diabetic nephropathy) till the study was terminated on 5thNov 
2007. Patients under study came with different history of disease & health condition. This model 
is explained with the help of figure 1 where X-axis denotes the duration of disease, and Y-axis 
denotes the level of SrCr.  The total lines from X-axis for any patient represents number of times 
the serum creatinine test was recommended and height of each line indicates its SrCr value.  The 
patient Pi (i= 1, 8, 50) belongs to group 1 and patients P5 and P20 to control group or group 0. The 
number of lines which crossed the cutoff value for the thi patient is the no. of successes for that 
respective patient. The number of lines below the cutoff value for the thi patient is not considered 
or count of zeros is not observed. Based on the number of successes we are able to estimate the 
onset of diabetic nephropathy. 
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Table 1. Descriptive statistics of 132 patients giving minimum, maximum, range and mean± standard 
deviation of age at diagnosis, duration of diabetes, fasting blood glucose(FBG), systolic blood pressure(SBP), 
diastolic blood pressure(DBP), low density lipoprotein(LDL) and serum creatinine(SrCr) for two groups i.e. 
control(Group 0 )and affected(Group 1). 
Variable Group 0 Group 1 
Age at diagnosis 
(years) 
minimum 35 29 
maximum 58 56 
range 23 27 
mean±S.D 44.011±4.36 45.003±5.28 
Duration of disease 
(years) 
minimum 5.6 29 
maximum 27 56 
range 21.4 27 
mean±S.D 10.2784±5.7 14.0931±5.0528 
FBG 
(mg/dl) 
 
minimum 62 120 
maximum 186 242 
range 124 122 
mean±S.D 133.8027±17.48 142.035±14.39 
DBP 
(mm Hg) 
minimum 68 76 
maximum 95 112.0 
range 27 36 
mean±S.D 82.3919±6.0789 91.9695±9.423 
SBP 
(mm Hg) 
minimum 110 110 
maximum 160 160 
range 50 50 
mean±S.D 125.1214±12.4007 142.8214±13.8815 
LDL 
(mg/dl) 
minimum 62 68 
maximum 186 132 
range 124 64 
mean±S.D 91.7973±18.75007 107.4417±14.2667 
SrCr 
(mg/dl) 
minimum 0.71 68 
maximum 1.39 132 
range 0.92 64 
mean±S.D 0.9982±0.15084 1.6686±0.28233 
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Figure 1. Zero truncated binomial model where X-axis denotes  of the diabetes, Y-axis denoting the level of 
Serum Creatine in mg/dl and number of vertical lines indicating the number of times Serum Creatinine 
recommended for i
th 
patient. 
 
2.2.1 Zero truncated binomial distribution Model 
Zero truncated samples from discrete distribution arise when the count of zeros are not 
considered. Let 1 2, ,..... nX X X  are independently distributed random variables following zero 
truncated binomial distribution with parameters ,in p . Then probability mass function for the 
thi  patient, is given by Johnson and Kotz [21] as. 
 
( )
(1 )
( )
(1 (1 ) )
i i i i
i
i
n x n x
x
i i n
c p p
P X x
p
    ; 1,2,...i ix n       (1) 
 
where in , the number of times the test is recommended to the
thi  patient,
  is known. SrCr ≥1.4 
mg/dl is considered as success, ix  denotes the number of successes and p is the probability of 
success. The parameter p is unknown and is estimated using maximum likelihood method as 
well as by residual bootstrapping method. 
 
2.2.2 Maximum likelihood method to estimate the parameter p 
The likelihood function for estimating p is given by: 
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Differentiating log L  with respect to p and then, equating the derivative to zero, the resulting 
equation comes out to be 
 
1 1
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i
n
n
i
n
n p
p
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Maximum likelihood estimate of p is obtained as p by solving the above equation by the method 
of iteration. This value of p , came out to be approximately equal to the   proportion of patients 
belonging to group-1(affected group). We also computed Var p and 95% confidence interval 
which may be considered as a special feature of this work. 
 
Var p = p (1 )p  / n  = p  (1- p )/ n        (4) 
 
. ( )C I p   = p    ±1.96*√ p  (1- p )/ n         (5) 
 
2.2.3 Residual Bootstrapping method to estimate the parameter p 
In this method linear regression model is fitted by taking iy , mean serum creatinine for the 
thi
   
patient, as response variable and ix , the  number of  successes ( no. of times the value of SrCr 
≥1.4 mg/dl ), as independent variable. Residual Bootstrapping is a method where resampling is 
applied for the errors alone and the entire vector of independent variables is not resampled 
suggested by Efron and Tibshirani [ 16]. 
 
i i iy x e            (6) 
 
Algorithm applied for estimating p is given as follows: 
 Step1- Using the full model (6), compute ˆiy predicted value and standardized residuals as: 
ˆ
ie =( iy - ˆiy )/ ˆ( )i iVar y y . 
 Step2- Generate the resample of residuals ˆie , giving dataset, {
*
ie }. 
 Step3- Create a new bootstrap sample dataset { *
iy } by 
*
iy = ˆiy +
*
ie ˆ( )i iVar y y . 
 Step4-  Use *
iy to estimate the parameter p . 
Repeat step 2-4 to generate *
iy for 50 samples, each with size 132. 
Estimated values of p  are depicted in table 2. We also computed the expected value, p , with 
corresponding variance and 95% confidence interval. These values were compared with those 
obtained by maximum likelihood method.  
 
2.2.4 The probability of renal disease /diabetic nephropathy for each patient with ZTBD model 
Under the above ZTBD model, we obtained the probability of renal disease for each patient. 
From the p , derived using maximum likelihood and residual bootstrapping methods, we 
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calculated P ( iX  ≤ no of successes), the cumulative mass function for each patient, is given 
below. 
 
( )
1
(1 )
( )
(1 (1 ) )
i i i ii
i
i
n x n xx
x
i n
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F x
p
   ;    1,2,...i ix n       (7) 
 
Then the expected number of successes required for thi  patient proceeding for diabetic 
nephropathy is given by. 
 
( )iE X = in p  / (1 (1 )
inp )         (8) 
 
3. Results 
 
Up-to-date pathological reports / records of diabetic patients, using a common path lab, were 
collected through a house to house Survey.  Retrospective study was conducted on the collected 
data. Since our study was focused on diabetic nephropathy only, patient’s data indicating effect 
on eyes, heart etc was excluded. A total of 132 diabetic patients were selected, (60 with and 72 
without renal complication), aged 44.45 ± 4.79 years (mean ± SD). The demographic details 
recorded were Age at the time of diagnosis, Duration of disease, FBG, DBP, SBP, LDL and SrCr 
as depicted in table 1.  Figure 2 depicted average value of SrCr under two groups (affected and 
controlled).  It can be observed from the figure 2 that patients with average (SrCr) ≤1.0 mg/dl are 
in control group and the patients with average (SrCr) ≥1.25 mg/dl are in affected group. Further, 
the proportion of patients in the affected group was distributed according to their diabetic history 
(i.e. duration of disease) and facts are displayed in table 2 and graphically illustrated in figure 3. 
 
 
Figure 2. Patients in two groups, control and affected group, according to mean Serum  Creatinine value 
measuring in mg/dl. Affected group is indicated by top line and bottom line indicates the cases under control 
group. 
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Table 2. Proportion of patients in the affected group was distributed according to their diabetic history. 
Duration of diabetes(yrs) Proportion of patients Cumulated proportion 
5-8 0.030303 0.030303 
8-11 0.060606 0.090909 
11-14 0.05303 0.143939 
14-17 0.075758 0.219697 
17-20 0.113636 0.333333 
>20 0.121212 0.454545 
 
 
Figure 3. Proportion of patients belonging to group 1 or affected group with respect to their diabetic history. 
 
3.1 Estimated value of p with corresponding variance and 95% confidence interval by the 
method of maximum likelihood and residual  bootstrapping method 
On substituting the values of the total number of times the SrCr test was recommended and the 
total number of times the value of SrCr ≥1.4 mg/dl as
1
n
ii
n = 996 and 
1
n
ii
x = 487, 
respectively, in equation (3) for the patients who belong to affected group, the maximum 
likelihood estimate of p was obtained as   p =.4555397. By applying residual bootstrapping 
method 50 different values of p  were estimated from each sample of size 132, which are 
displayed in table 3. Further, t-test for single mean was applied to test for p  =0.445545 and 
calculated value of t came out to be 0.791, which showed that the generated sample was accepted 
for p = p . Thus, p  =0.445545, was considered as estimate of p obtained by residual 
bootstrapping method. The estimates of p , Expected ( p ), Variance ( p ) & 95% Confidence 
interval ( p ) were obtained by both the method of maximum likelihood and residual 
bootstrapping method and are displayed in table 4. The 95% Confidence interval ( p ) from 
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residual bootstrapping was found to be wider i.e. (0.4229133, 0.4681766) as compared to 
(0.4435269, 0.4675524), obtained by maximum likelihood method. 
 
Table 3.  Indicates 50 different values of p using Residual Bootstrapping. 
0.445545 0.4924242 0.4090909 0.3257576 0.2878788 0.4621212 0.2727273 
0.5227273 0.4469697 0.2424242 0.2878788 0.4621212 0.3257576 0.4166667 
0.5151515 0.3863636 0.4848485 0.4318182 0.5757576 0.4242424 0.5909091 
0.3560606 0.4015152 0.4772727 0.5151515 0.4469697 0.5681818 0.4242424 
0.530303 0.530303 0.3636364 0.4015152 0.3560606 0.3560606 0.5227273 
0.3560606 0.4469697 0.4848485 0.469697 0.4242424 0.5075758 0.5227273 
0.3181818 0.4545455 0.4772727 0.4469697 0.4621212 0.4015152 0.4924242 
0.5075758       
 
Table 4. The estimates of p , Expected ( p  ), Variance ( p  ) & 95% Confidence interval ( p ) obtained by the 
method of maximum likelihood and residual bootstrapping. 
Method p  Expected ( p  ) Variance ( p  ) 95% Confidence interval ( p ) 
Maximum 
Likelihood 
0.4555397 0.45454545 0.00187829 (0.4435269,0.4675524) 
Residual 
Bootstrapping 
0.445545 0.458743 0.000499 (0.4229133,0.4681766) 
 
3.2 The probability of renal disease /diabetic nephropathy for every patient with ZTBD 
model 
Based on p  obtained by maximum likelihood method, ~ ( ,0.4555397)i iX ZTBD n , with 
known in , Using this ZTBD model we calculated probability mass function and cumulative 
function for each patient, as the number of times the SrCr test was recommended was different 
for different patients. Using figure 1, for each patient under affected group, counted the number 
of times the serum creatinine value crossed the normal range for the thi patient, and obtained ix . 
We obtained ( )i iP X x or probability of occurrence of diabetic nephropathy and mean number 
of successes for all 60 patients as depicted in column (2) and column (4) respectively in table 5. 
Here we used the value of p  obtained by residual bootstrapping method, 
~ ( ,0.445545)i iX ZTBD n , with known in . Proceeding in the same manner as for maximum 
likelihood method, ( )i iP X x or probability of occurrence of diabetic nephropathy and mean 
number of successes for all 60 patients were obtained and are depicted in column (3) and column 
(5) respectively in table 5. 
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Table 5 (a). Probability of occurrence of Diabetic Nephropathy, mean number  of times the SrCr crossing the 
normal range, using maximum likelihood and Residual bootstrapping methods under ZTBD. 
Duration 
(yrs) 
Probability 
of diabetic nephropathy 
 
Expected no. of successes 
 
Maximum 
likelihood 
estimator 
Bootstrapping 
estimator 
Maximum 
likelihood 
estimator 
Bootstra
pping 
estimator 
Proceeding for 
diabetic 
nephropathy 
6 0.21241 0.24211 1 2 4 
7 0.06078 0.03706 0 1 5 
7 0.05987 0.05774 0 0 3 
7.8 0.87266 0.79944 11 12 6 
8 0.09377 0.0904 1 1 5 
8 0.14242 0.13805 1 1 4 
9 0.03601 0.03454 0 0 4 
9 0.06078 0.05827 0 0 5 
9.6 0.09617 0.09624 1 1 6 
10 0.03713 0.035 1 1 8 
10 0.01537 0.01449 0 0 4 
10 0.25502 0.2484 3 2 5 
10.4 0.26612 0.2541 3 2 5 
11 0.05987 0.05774 0 0 6 
11.4 0.00954 0.00547 0 0 7 
12 0.01974 0.01753 0 0 7 
12 0.87266 0.79944 12 11 6 
13 0.64537 0.54807 11 9 8 
13 0.99611 0.98955 16 16 7 
13.4 0.18541 0.09974 3 2 7 
13.6 0.80649 0.80649 12 11 7 
15 0.97948 0.97808 18 18 7 
15 0.91011 0.90566 15 15 8 
15.2 0.15696 0.15122 2 2 6 
15.6 0.99681 0.992 19 19 9 
16 0.81062 0.71934 11 9 6 
16 0.9467 0.85553 15 14 7 
16 0.95359 0.91268 14 13 7 
16 0.99566 0.99932 21 21 10 
16.6 0.80396 0.79641 14 14 8 
17 0.08797 0.08577 2 2 10 
17 0.95947 0.90049 20 19 10 
17 0.999 0.99091 21 21 10 
17.2 0.72935 0.63529 12 10 7 
17.6 0.94381 0.91011 16 15 8 
18 0.00009 0.00005 0 0 9 
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Table 5 (b). Probability of occurrence of Diabetic Nephropathy, mean number  of times the SrCr crossing the 
normal range, using maximum likelihood and Residual bootstrapping methods under ZTBD. 
18 0.73441 0.64926 13 15 9 
18 0.97948 0.97808 18 18 8 
19 0.1058 0.1332 3 2 8 
19 0.13581 0.13552 3 3 8 
19 0.37327 0.36287 7 7 8 
19 0.86174 0.85553 16 15 11 
20 0.49482 0.481202 8 8 8 
20 0.9944 0.99394 18 18 8 
21 0.05438 0.035 1 1 8 
21.2 0.03873 0.02397 0 0 7 
21.4 0.02601 0.00664 0 0 11 
22 0.00213 0.00044 0 0 11 
22.2 0.00471 0.00432 0 0 11 
22.6 0.00725 0.00668 0 0 10 
23 0.99969 0.99874 17 17 8 
23 0.00471 0.00432 0 0 11 
23.6 0.00725 0.00668 0 0 10 
24 0.11971 0.08338 2 1 10 
24 0.18541 0.13103 3 2 9 
24.4 0.86174 0.85553 16 15 8 
26 0.85213 0.84433 21 21 12 
26 0.85014 0.84006 21 21 12 
26.6 0.99681 0.98382 23 23 11 
 
3.3 Comparison between two groups, less advanced nephropathy with advanced 
nephropathy 
The column (6) of table 5 is representing the expected number of successes required for 
thi patient proceeding to advanced diabetic nephropathy. Patients in affected group were with 
different diabetic history and different renal health.  To identify patients with advanced 
nephropathy, mean number of successes obtained through maximum likelihood method and 
residual bootstrapping method was compared with the mean number of successes required for 
any patient proceeding for DN.  It was found  that 27 patients i.e. 20.45% of 132 subjects, whose 
mean number of successes, obtained through maximum likelihood method and residual 
bootstrapping method, was greater than or equal to the number of successes required for any 
patient, proceeded to advanced diabetic nephropathy. Thus, under ZTBD model, 132 patients 
were classified under three groups, 72 under control, 33 had less advanced nephropathy and 27 
had proceeded with advanced nephropathy. By applying t-test of difference of means on the  two 
groups of patients,33 less advanced nephropathy and 27 advanced nephropathy, under affected 
group of 60 patients were found to be significantly different and the calculated value of t came 
out to be 9.61 with p<0.001. Results in table 6 indicate the details of 27 patients, belonging to 
advanced nephropathy group, with respect to  duration of disease and mean number of times 
serum creatinine crossed normal range (using ML and bootstrapping methods) under ZTBD. 
These results regarding the expected number of successes obtained from both the methods have 
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been graphically illustrated in figure 4. It can be observed from the graph as well as from  table 6 
that the results obtained by both the methods are close to each other. SPSS for Windows, Version 
15 statistical package was used for calculation and analysis. 
 
Table 6. Mean number of successes only for those patients who proceeded for  Advanced Diabetic 
Nephropathy  along with their duration ,from maximum likelihood and residual bootstrapping methods. 
Duration 
Of diabetes 
(years) 
Expected no. of successes 
 
Maximum 
Likelihood 
estimator 
Bootstrap
ping 
estimator 
Proceeding for 
diabetic 
nephropathy 
7.8 11 12 6 
12 12 11 6 
13 11 9 8 
13 16 16 7 
13.6 12 11 7 
15 18 18 7 
15 15 15 8 
15.6 19 19 9 
16 11 9 6 
16 15 14 7 
16 14 13 7 
16 21 21 10 
16.6 14 14 8 
17 20 19 10 
17 21 21 10 
17.2 12 10 7 
17.6 16 15 8 
18 13 15 9 
18 18 18 8 
19 16 15 7 
20 8 8 8 
20 18 18 8 
23 17 17 8 
24.4 16 15 8 
26 21 21 12 
26 21 21 12 
26.6 23 23 11 
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Figure 4. Mean number of successes only for those patients who proceeded for  Advanced Diabetic 
Nephropathy obtained from maximum likelihood and residual bootstrapping methods. 
 
 
4. Discussion 
 
The present study demonstrates that an increase in value of serum creatinine in type-2 diabetic 
patients predicts the progression of nephropathy. The major use of estimating the probability of 
occurrence of diabetic nephropathy is that in future studies it may provide greater sensitivity for 
detecting patients with diabetic nephropathy. It may allow one to gain deeper insight into the 
various differences that may exist between the treatments suggested by previous studies i.e. by 
the DCCT Research Group and UK Prospective Diabetes Study Group[ 19,20] given to type -2 
diabetic patients.  
Under the present ZTBD model, out of 132 patients 45.45% had non zero probability of diabetic 
nephropathy with mean duration of diabetes as 15.99 yrs which is almost consistent with the 
previous findings which suggest that diabetic nephropathy develop in 20 – 40 % of patients 
within 10 to 15 years after the onset of diabetes [13]. Further, this model divides the 60 patients 
of affected group  into two group sizes 33 and 27. In the first group with less advanced 
nephropathy, the expected number of times SrCr crossed the normal range, obtained from 
maximum likelihood and residual bootstrapping methods, came out to be less than the expected 
number required for proceeding for DN. In the second group with advanced nephropathy, the 
expected number of times SrCr crossed the normal range, obtained from maximum likelihood 
and residual bootstrapping methods, came out to be more than or equal to the expected number 
required for proceeding for DN. The findings of this paper through ZTBD model are consistent 
with the observed facts, i.e., out of total of 132 subjects, 72 had mean serum creatinine  
1.0mg/dl under control. Out of the remaining 60 patients of the affected group, 33 had mean 
SrCr equal to 1.42 mg/dl, under less advanced nephropathy and 27 had mean SrCr equal to 
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1.91mg/dl, under advanced nephropathy group as given in table 7. The classification obtained 
from the ZTBD model as well as from the observed almost matches with the results obtained by 
Abs-Lewis EJ. 
 
Table 7. The descriptive statistics for the three groups, viz., control, less advanced nephropathy and advanced 
nephropathy. 
Groups Group size Mean SrCr Standard Deviation 
Control Group 72 .9780 .12616 
Less advanced DN group 33 1.4245 .07665 
Advanced  DN group 27 1.9137 .20888 
Total 132 1.2810 .39610 
 
Previous studies suggest that there is a constant deterioration of renal function of the diabetic 
patients over time or progression of nephropathy over time [20]. It can be observed from the 
present ZTBD model that out of a total of 56 patients with less than 10 years of diabetes 
duration, 8 are under less advanced nephropathy group and only 1 patient is under advanced 
nephropathy group. Where as in a total of 21 patients with greater than 20 years of diabetes 
duration, 11 are under less advanced nephropathy group and only 6 patients are under advanced 
nephropathy group. To show that the progression of nephropathy depends on the duration of 
diabetes we applied Karl-Pearson’s chi square goodness-of-fit test for independence of attributes, 
where calculated value of chi-square came out to be 
2
(6) =51.39  with p<0.001 Thus we 
conclude that there is a constant deterioration of renal function of the diabetic patients over time 
or progression of nephropathy over time. Complete detail of results is depicted in table 8. The 
results are completely in accordance with past studies which suggest a link between development 
and progression of diabetic nephropathy and duration of diabetes in type 2 diabetic patients [20]. 
 
Table 8. Progression of nephropathy depends on the duration of diabetes with 132 type-2 diabetic patients. 
 Group accord disease progression Total 
0 1 2  
Duration 
of 
disease 
<10 Counted 
Expected Count 
47 
30.5 
8 
14 
1 
11.5 
56 
56.0 
10-15 Counted 
Expected Count 
11 
12.5 
8 
5.8 
4 
4.7 
23 
23.0 
15-20 Counted 
Expected Count 
10 
17.5 
6 
8.0 
16 
6.5 
32 
32.0 
                   ≥20                                                                                Counted
Expected Count 
4 
11.5 
11 
5.3 
6 
4.3 
21 
21.0 
Total Counted 
Expected Count 
72 
72.0 
33 
33.0 
27 
27.0 
132 
132.0 
 
In conclusion, the present study suggests that increased serum creatinine levels are strongly 
associated with the development of diabetic nephropathy and the results obtained in this paper, 
based on marker serum creatinine, are also comparable with the previous results which are based 
on albumin urea. 
 
 
Identifying patients with diabetic nephropathy based on serum creatinine under zero truncated model 
42 
References 
 
[1]. Brenner, B.M., Keane, W.F., Grunfeld, J.P., et al (2003). The risk of developing end-
stage renal disease in patients with type 2 diabetes and nephropathy: The RENAL Study. 
Kidney International, 63, 1499 – 507. 
[2]. Molitch, M.E., DeFronzo, R.A., Franz, M.J., et al (2004). Nephropathy in diabetes. 
Diabetes Care, 27, S79 – S83. 
[3]. World Health Organization (2004). The diabetes program. 
http://www.who.int/diabetes/en. 
[4]. Mykkänen, L., Haffner, S.M., et al (1994). Microalbuminuria precedes the development 
of NIDDM. Diabetes, 43, 552 – 557. 
[5]. Azevedo, M.J., Gross, J.L., Silveiro, S.P.,et al (2000). Diabetic nephropathy: diagnosis, 
prevention, and treatment. Diabetes Care, 28, 164 – 176. 
[6]. Agarwal, A.K., Singla, S., Garg, U., et al, (2005). Glomerular Filtration Rate and Total 
Kidney Volume in Cases of Recent Onset Type-2 Diabetes Mellitus. Indian Academy of 
Clinical Medicine , 288 Journal, 6 (1). 
[7]. Adler, A.I., Stevens, R.J., Manley, S.E., et al (2003). Development and progression of 
nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study 64. 
Kidney International, 63, 225 – 232. 
[8]. Avram, M.M., Hurtado, H. (1989). Renal Size and Function in Diabetic Nephropathy. 
Nephron , 52, 259 – 261. 
[9]. Khan, S.A., Muhammad, H., Rehman, G. (2005). Studies on Diabetic Nephropathy and 
Secondary Diseases in Type 2 Diabetes. Int. J. Diab. Dev. Countries, 25. 
[10]. Aalen, O.O., Borgan, Gunnes, N. (2007). Estimating stage occupation probabilities in 
non-Markov models. Lifetime Data Analysis, 13, 211 – 240. 
[11]. Hussain, G., Muhammad, I.S. (2007). Bootstrap Confidence Interval for Parameter ‘p’ of 
Truncated Negative Binomial Distribution. Journal of Management and Social Sciences, 
3 (2), 77 – 86. 
[12]. Frydman, H. (1995). Nonparametric estimation of a Markov ‘illness-death’ process from 
interval-censored observations, with application to diabetes survival data. Biometrika, 82 
(4), 773 – 789. 
[13]. Mazze, Strock, Simonson and Bergenstal (2005). Staged-Diabetes Management, A 
Systematic Approach. Second edition: John Wiley& Sons. 
[14]. Davison, A.C., Hinkley, D.V. (1997). Bootstrap Methods and Their Application. 
Cambridge: University Press. 
[15]. DiCiccio, T.J., Efron, B. (1996). Bootstrap confidence intervals. Statististical Science, 11, 
189 – 212. 
[16]. Efron, B., Tibshirani, R. (1993). An Introduction to the Bootstrap. New York: Chapman 
and Hall. 
[17]. Enzo, B., Vittorio, C., et al (2003). Probabilistic approach to developing nephropathy in 
diabetic patient with retinopathy. Statistics in Medicine, 20 (24), 3889 – 3897. 
[18]. Andersen, P.K. (1988). Multistate models in survival analysis: a study of nephropathy 
and mortality in diabetes. Statistics in Medicine, 7, 661 – 670. 
Grover G., Gadpayle A.K., Alka Sabharwal, Electron. J. App. Stat. Anal., Vol 3, Issue 1 (2010), 28 – 43. 
43 
[19]. The DCCT Research Group.  (1993). The effect of intensive treatment of diabetes on the 
development and progression of long-term complications in insulin-dependent diabetes 
mellitus. N Engl J Med, 329, 977 – 986. 
[20]. UK Prospective Diabetes Study Group. (1998). Intensive blood glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type- 2 diabetes’ UKPDS 33. Lancet, 352, 837 – 853. 
[21]. Johnson, N.L., Kotz, S. (1969). Discrete Distributions. New York, Chichester, Brisbane, 
Toronto, Singapore: John Wiley &Sons. 
